Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04960202 · ClinicalTrials.gov registry record · Phase 2
EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19
A Phase 2 study of COVID-19, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 2,091
- Enrollment target
- 20
- Study locations
NCT04960202: Completed Phase 2 study of COVID-19, sponsored by Pfizer.
NCT04960202 is a Phase 2 study of COVID-19 that has completed, run by Pfizer. The registered enrollment target is 2,091 participants, below the 38,458-participant average among 298 other COVID-19 trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04960202, a Phase 2 study of COVID-19, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 2,091 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether PF-07321332/ritonavir is safe and effective for the treatment of adults who are ill with COVID-19 and do not need to be in the hospital, but are at an increased risk of developing severe illness. Throughout the study period, provision will be made to allow study visits to be conducted at a participant's home or another non-clinic location if available. The total study duration is up to 24 weeks.
Primary Outcome
Percentage of participants with COVID-19 related hospitalization or death from any cause during the first 28 days of the study was estimated using the Kaplan-Meier (KM) method. Using KM method, survival probability for each time interval was calculated as the number of participants surviving divided by the number of participants at risk. Participants who had the event, dropped out, or moved out were not counted as "at risk" i.e., participants who were lost were considered "censored" and were not
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ritonavir
- DRUG PF-07321332
Study Locations (20)
Florida
- Xera Med Research - Boca Raton
- MOORE Clinical Research, Inc. - Brandon
- Innovative Research of West Florida, Inc. - Clearwater
- Herco Medical and Research Center Inc - Coral Gables
- Advance Clinical Research Group - Cutler Bay
- Beautiful Minds Clinical Research Center - Cutler Bay
- Qway Research - Hialeah
- Eastern Research Inc - Hialeah
- Inpatient Research Clinic - Hialeah
California
- Hope Clinical Research - Canoga Park
- Ascada Research - Fullerton
- Atella Clinical Research LLC. - La Palma
- Ark Clinical Research - Long Beach
- American Institute of Research - Los Angeles
- South Bay Clinical Research Institute - Redondo Beach
- Hope Clinical Research (COVID Satellite Site) - West Hills
Arizona
- The Institute for Liver Health dba Arizona Clinical Trials - Mesa
- The Institute for Liver Health dba Arizona Clinical Trials - Tucson
Alabama
- Cahaba Research Inc - Pelham
Colorado
- Future Innovative Treatments, LLC - Colorado Springs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,091 participants |
| Start Date | 2021-07-16 |
| Est. Completion | 2022-04-25 |
| Phase | Phase 2 |
What the finished NCT04960202 record still lists
NCT04960202 is an interventional study that assigns participants to a tested intervention. Its 2,091 participants enrollment target places it among the larger protocols in the corpus, below the 38,458-participant average among 298 other COVID-19 trials with a reported enrollment target (95% lower).
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT04960202 names 20 study sites across 5 states, led by Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT04960202 about?
NCT04960202 is a clinical study titled "EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19". The purpose of this study is to determine whether PF-07321332/ritonavir is safe and effective for the treatment of adults who are ill with COVID-19 and do not need to be in the hospital, but are at an increased risk of developing severe illness. Throughout the study period, provision will be made to...
What is the current status of trial NCT04960202?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 2,091 participants. The study started on 2021-07-16. Estimated completion is 2022-04-25.
What conditions does trial NCT04960202 study?
This clinical trial studies the following conditions: COVID-19.
What interventions are being tested in trial NCT04960202?
The interventions under investigation include: Placebo (DRUG), Ritonavir (DRUG), PF-07321332 (DRUG).
Who is sponsoring clinical trial NCT04960202?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04960202 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04960202's enrollment target sits among peer trials
2,091 43rd of 298 higher than 256 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
A Nasal Treatment for COVID-19
RECRUITING · Phase 2
-
Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults
RECRUITING · Phase 2
-
Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19
RECRUITING · Phase 2
-
Low Dose Whole Lung Radiation Therapy for Patients With COVID-19 and Respiratory Compromise
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04649242 · 2,100 participants · Phase 3
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
- NCT05206331 · 2,100 participants · Phase 4
CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study
- NCT05270499 · 2,100 participants
Aveir VR Real-World Evidence Post-Approval Study
- NCT06324981 · 2,100 participants · NA
Using AI Text Messaging to Improve AHA's Life's Essential 8 Health Behaviors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI